• +1-646-491-9876
    • +91-20-67278686

    Search

    Leiomyosarcoma - Pipeline Review, H1 2017

    Leiomyosarcoma - Pipeline Review, H1 2017

    • Report Code ID: RW0001709458
    • Category Pharmaceuticals
    • No. of Pages 144
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Leiomyosarcoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Pipeline Review, H1 2017, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape.

    Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Leiomyosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Leiomyosarcoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Leiomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

    Leiomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Leiomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Leiomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Leiomyosarcoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Leiomyosarcoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Leiomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Leiomyosarcoma - Overview
    Leiomyosarcoma - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Leiomyosarcoma - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Leiomyosarcoma - Companies Involved in Therapeutics Development
    Advenchen Laboratories LLC
    BeiGene Ltd
    Cell Medica Ltd
    Karyopharm Therapeutics Inc
    Merck & Co Inc
    Merck KGaA
    Mirati Therapeutics Inc
    Novartis AG
    Pfizer Inc
    Vicore Pharma AB
    Yooyoung Pharmaceutical Co Ltd
    Leiomyosarcoma - Drug Profiles
    AL-3818 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    avelumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    axitinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    baltaleucel-T - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BGB-290 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C-21 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    everolimus - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mocetinostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pembrolizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    selinexor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YYB-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Leiomyosarcoma - Dormant Projects
    Leiomyosarcoma - Discontinued Products
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Leiomyosarcoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Leiomyosarcoma - Pipeline by Advenchen Laboratories LLC, H1 2017
    Leiomyosarcoma - Pipeline by BeiGene Ltd, H1 2017
    Leiomyosarcoma - Pipeline by Cell Medica Ltd, H1 2017
    Leiomyosarcoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017
    Leiomyosarcoma - Pipeline by Merck & Co Inc, H1 2017
    Leiomyosarcoma - Pipeline by Merck KGaA, H1 2017
    Leiomyosarcoma - Pipeline by Mirati Therapeutics Inc, H1 2017
    Leiomyosarcoma - Pipeline by Novartis AG, H1 2017
    Leiomyosarcoma - Pipeline by Pfizer Inc, H1 2017
    Leiomyosarcoma - Pipeline by Vicore Pharma AB, H1 2017
    Leiomyosarcoma - Pipeline by Yooyoung Pharmaceutical Co Ltd, H1 2017
    Leiomyosarcoma - Dormant Projects, H1 2017
    Leiomyosarcoma - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Leiomyosarcoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Advenchen Laboratories LLC
    BeiGene Ltd
    Cell Medica Ltd
    Karyopharm Therapeutics Inc
    Merck & Co Inc
    Merck KGaA
    Mirati Therapeutics Inc
    Novartis AG
    Pfizer Inc
    Vicore Pharma AB
    Yooyoung Pharmaceutical Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//leiomyosarcoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//leiomyosarcoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//leiomyosarcoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments